Acta Pharmaceutica, Vol. 73 No. 3, 2023.
Original scientific paper
https://doi.org/10.2478/acph-2023-0034
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
ANA VAVLUKIS
orcid.org/0000-0001-7621-5655
KRISTINA MLADENOVSKA
orcid.org/0000-0003-2503-4699
; University Ss Cyril and Methodius, Faculty of Pharmacy, 1000 Skopje, RN Macedonia
KATARINA DAVALIEVA
orcid.org/0000-0002-0878-6533
; Macedonian Academy of Sciences and Arts, Research Center for Genetic Engineering and Biotechnology „Georgi D. Efremov“, 1000 Skopje, RN Macedonia
MARIJA VAVLUKIS
; University Ss Cyril and Methodius, Faculty of Medicine, 1000 Skopje, RN Macedonia
ALEKSANDAR DIMOVSKI
; University Ss Cyril and Methodius, Faculty of Pharmacy, 1000 Skopje, RN Macedonia; Macedonian Academy of Sciences and Arts, Research Center for Genetic Engineering and Biotechnology „Georgi D. Efremov“, 1000 Skopje, RN Macedonia
Abstract
The advancements in proteomics have provided a better understanding of the functionality of apolipoproteins and lipoprotein-associated proteins, with the HDL lipoprotein fraction being the most studied. The focus of this study was to evaluate the HDL proteome in dyslipidemic subjects without an established cardiovascular disease, as well as to test whether rosuvastatin treatment alters the HDL proteome. Patients with primary hypercholesterolemia or mixed dyslipidemia were assigned to 20 mg/day rosuvastatin and blood samples were drawn at study entry and after 12 weeks of treatment. A label-free LC-MS/MS protein profiling was conducted, coupled with bioinformatics analysis. Sixty-nine HDL proteins were identified, belonging to four main biological function clusters: lipid transport and metabolism; platelet activation, degranulation, and aggregation, wound response and wound healing; immune response; inflammatory and acute phase response. Five HDL proteins showed statistically significant differences in the abundance (Anova ≤ 0.05), before and after rosuvastatin treatment. Platelet factor 4 variant (PF4V1), Pregnancy-specific beta-1-glycoprotein 2 (PSG2), Profilin-1 (PFN1) and Keratin type II cytoskeletal 2 epidermal (KRT2) showed decreased expressions, while Integrin alpha-IIb (ITGA2B) showed an increased expression after treatment with rosuvastatin. The ELISA validation of PFN1 segregated the subjects into responders and non-responders, as PFN1 levels after rosuvastatin were shown to mostly depend on the subjects' inflammatory phenotype. Findings from this study introduce novel insights into the HDL proteome and statin pleiotropism.
Keywords
proteomics; high-density lipoprotein; rosuvastatin; Profilin-1; phospholipid transfer protein; platelet factor 4 variant
Hrčak ID:
307864
URI
Publication date:
30.9.2023.
Visits: 637 *